PolyPid Ltd. (PYPD)

Market Cap	21.91M
Revenue (ttm)	n/a
Net Income (ttm)	-26.86M
Shares Out	6.80M
EPS (ttm)	-6.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,910
Open	3.500
Previous Close	3.460
Day's Range	3.220 - 3.680
52-Week Range	2.370 - 9.200
Beta	1.33
Analysts	Strong Buy
Price Target	12.00 (+272.67%)
Earnings Date	Feb 12, 2025

About PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. The company has re...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2020
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: PYPD
• Website: https://www.polypid.com

Analyst Forecast

According to 2 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 272.67% from the latest price.

Price Target

$12.0

(272.67% upside)

Analyst Consensus: Strong Buy